Results 31 to 40 of about 4,105,290 (355)

Neutralizing monoclonal antibodies for treatment of COVID-19

Nature reviews. Immunology, 2021
Several neutralizing monoclonal antibodies (mAbs) to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been developed and are now under evaluation in clinical trials.
P. Taylor, A. Adams, M. Hufford, I. de la Torre, K. Winthrop, R. Gottlieb   +5 more
semanticscholar   +1 more source

Potent SARS-CoV-2 Neutralizing Antibodies Directed Against Spike N-Terminal Domain Target a Single Supersite

bioRxiv, 2021
Numerous antibodies that neutralize SARS-CoV-2 have been identified, and these generally target either the receptor-binding domain (RBD) or the N-terminal domain (NTD) of the viral spike.
G. Cerutti, Yicheng Guo, T. Zhou, J. Gorman, Myungjin Lee, M. Rapp, E. Reddem, Jian Yu, Fabiana A. Bahna, Jude S. Bimela, Yaoxing Huang, Phinikoula S. Katsamba, Lihong Liu, M. Nair, Reda Rawi, A. Olia, Pengfei Wang, G. Chuang, D. Ho, Zizhang Sheng, P. Kwong, L. Shapiro   +21 more
semanticscholar   +1 more source

Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability

Science, 2020
Sites of vulnerability in SARS-CoV-2 Antibodies that neutralize severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) could be an important tool in treating coronavirus disease 2019 (COVID-19). Brouwer et al.
P. Brouwer, Tom G. Caniels, K. van der Straten, Jonne L. Snitselaar, Y. Aldon, S. Bangaru, J. Torres, Nisreen M. A. Okba, M. Claireaux, G. Kerster, A. Bentlage, M. M. van Haaren, Denise Guerra, J. Burger, E. Schermer, K. Verheul, N. van der Velde, Alex van der Kooi, J. van Schooten, M. V. van Breemen, Tom P. L. Bijl, Kwinten Sliepen, A. Aartse, R. Derking, I. Bontjer, N. Kootstra, W. Wiersinga, G. Vidarsson, B. Haagmans, A. Ward, G. D. de Bree, R. Sanders, M. V. van Gils   +32 more
semanticscholar   +1 more source

Animal Models of IgE Anaphylaxis

Biology, 2023
Allergies and atopy have emerged as significant public health concerns, with a progressively increasing incidence over the last two decades. Anaphylaxis is the most severe form of allergic reactions, characterized by a rapid onset and potentially fatal ...
Aurélie Gouel-Chéron, Alice Dejoux, Emma Lamanna, Pierre Bruhns   +3 more
doaj   +1 more source

Potent Neutralizing Antibodies against SARS-CoV-2 Identified by High-Throughput Single-Cell Sequencing of Convalescent Patients’ B Cells

Cell, 2020
The COVID-19 pandemic urgently needs therapeutic and prophylactic interventions. Here, we report the rapid identification of SARS-CoV-2-neutralizing antibodies by high-throughput single-cell RNA and VDJ sequencing of antigen-enriched B cells from 60 ...
Yunlong Cao, B. Su, Xianghua Guo, Wenjie Sun, Yongqiang Deng, L. Bao, Qinyu Zhu, Xu Zhang, Yinghui Zheng, Chenyan Geng, Xiaoran Chai, Runsheng He, Xiaofeng Li, Qi Lv, Hua Zhu, Wei Deng, Yanfeng Xu, Yanjun Wang, Luxin Qiao, Ya-fang Tan, Liyang Song, Guopeng Wang, Xiaoxia Du, Ning Gao, Jiangning Liu, Junyu Xiao, X. Su, Z. Du, Yingmei Feng, Chuan Qin, C. Qin, R. Jin, X. Xie, CH Vlclvh   +33 more
semanticscholar   +1 more source

Anti-drug antibodies to antibody-based therapeutics in multiple sclerosis. [PDF]

, 2021
Multiple sclerosis is the major demyelinating autoimmune disease of the central nervous system. Relapsing MS can be treated by a number of approved monoclonal antibodies that currently target: CD20, CD25 (withdrawn), CD49d and CD52.
Asardag, AN, Baker, D, Efimov, A, Kang, AS, Quinn, OA   +4 more
core   +1 more source

Acknowledgement to Reviewers of Antibodies in 2019

Antibodies, 2020
The editorial team greatly appreciates the reviewers who have dedicated their considerable time andexpertise to the journal’s rigorous editorial process over the past 12 months[...]
Antibodies Editorial Office
doaj   +1 more source

Antibodies and antibody-derived analytical biosensors [PDF]

Essays in Biochemistry, 2016
The rapid diagnosis of many diseases and timely initiation of appropriate treatment are critical determinants that promote optimal clinical outcomes and general public health. Biosensors are now being applied for rapid diagnostics due to their capacity for point-of-care use with minimum need for operator input.
Sharma, Shikha, Byrne, Hannah, O'Kennedy, Richard J.   +2 more
openaire   +2 more sources

Intracellular Antibodies for Drug Discovery and as Drugs of the Future [PDF]

, 2023
The application of antibodies in cells was first shown in the early 1990s, and subsequently, the field of intracellular antibodies has expanded to encompass antibody fragments and their use in target validation and as engineered molecules that can be ...
Rabbitts, TH, T. H. Rabbitts
core   +1 more source

Neuropathophysiological potential of Guillain-Barré syndrome anti-ganglioside-complex antibodies at mouse motor nerve terminals [PDF]

, 2011
Objectives:  Anti-ganglioside antibodies are present in approximately half of Guillain–Barré syndrome (GBS) patients. Recently, it has been shown that a considerable proportion of these patients has serum antibodies against antigenic epitopes formed by a
Susumu Kusunoki, Tio-Gillen, Anne P., Plomp, J.J., Kusunoki, Susumu, Tio-Gillen, A.P., Willison, H.J., Broos, Ludo A.M., Ueda, M., Mark L. Kuijf, Ludo A. M. Broos, Kuijf, Mark L., Jacobs, B.C., Greenshields, Kay N., Jacobs, Bart C., Zitman, F.M.P., Hugh J. Willison, Anne P. Tio-Gillen, Masami Ueda, Kuijf, M.L., Jaap J. Plomp, Kusunoki, S., Greenshields, K.N., Plomp, Jaap J., Femke M. P. Zitman, Broos, L.A.M., Kay N. Greenshields, Ken-ichi Kaida, Willison, Hugh J., Bart C. Jacobs, Kaida, Ken Ichi, Kaida, K.I., Ueda, Masami, Zitman, Femke M.P.   +32 more
core   +1 more source